- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, lists possible policy changes that would strengthen the safety net.
Transcript
What policy changes are you looking to see that would strength the safety net?
One of the big changes we would like to see is spreading the out-of-pocket cost for Medicare patients throughout the benefit year rather than having it all hit in the beginning of the year. I think a lot of patients really could probably afford their out of pocket cost if they could spread it out. So, we’re hoping that there will be some attention towards that. We would also like to see at least one highly effective drug for each indication being placed on a non-specialty tier. So, having a copay rather than a coinsurance for at least one of the innovators specialty drugs for each indication. Then, of course, the third and one you hear more often is putting an out-of-pocket limit on the catastrophic phase in Medicare. We think that that would be helpful but it’s not gonna affect that many people. There’s only about 2% of Medicare beneficiaries who reach the catastrophic threshold.
AI Meets Medicare: Inside CMS’s WISeR Model With Sanjay Doddamani, MD, MBA, Part 2
August 5th 2025In this second part of his interview with The American Journal of Managed Care®, Sanjay Doddamani, MD, MBA, a former senior advisor to CMMI and founder and CEO of Guidehealth, continues a dialogue on the future of value-based care and the promise—and limits—of AI-enabled innovation, reflecting on challenges like rising Medicare costs and patients’ growing financial burdens.
Read More
Long-Term Lebrikizumab Provides Sustained Skin Clearance in Atopic Dermatitis
August 5th 2025In this subanalysis of data from the ADjoin trial of lebrikizumab, the interleukin-13 receptor inhibitor that is also a monoclonal antibody showed itself to be effective over the long term in patients with atopic dermatitis on maintenance therapy.
Read More
